Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
SHATTUCK LABS INC (STTK) Stock Price & Overview
NASDAQ:STTK • US82024L1035
Current stock price
6.99 USD
-0.16 (-2.24%)
At close:
6.9886 USD
0 (-0.02%)
After Hours:
The current stock price of STTK is 6.99 USD. Today STTK is down by -2.24%. In the past month the price increased by 8.88%. In the past year, price increased by 602.02%.
STTK Key Statistics
52-Week Range0.712 - 8.33
Current STTK stock price positioned within its 52-week range.
1-Month Range6.36 - 8.33
Current STTK stock price positioned within its 1-month range.
- Market Cap
- 528.304M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.77
- Dividend Yield
- N/A
STTK Stock Performance
Today
-2.24%
1 Week
-9.69%
1 Month
+8.88%
3 Months
+80.62%
Longer-term
6 Months +264.06%
1 Year +602.02%
2 Years -5.28%
3 Years +152.35%
5 Years -74.24%
10 Years N/A
STTK Stock Chart
STTK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to STTK. When comparing the yearly performance of all stocks, STTK is one of the better performing stocks in the market, outperforming 99.25% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
STTK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STTK. While STTK has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
STTK Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.12
Revenue Reported
EPS Surprise 13.92%
Revenue Surprise -100.00%
STTK Forecast & Estimates
13 analysts have analysed STTK and the average price target is 12.65 USD. This implies a price increase of 80.94% is expected in the next year compared to the current price of 6.99.
For the next year, analysts expect an EPS growth of 30.92% and a revenue growth -100% for STTK
Analysts
Analysts81.54
Price Target12.65 (80.97%)
EPS Next Y30.92%
Revenue Next Year-100%
STTK Financial Highlights
Over the last trailing twelve months STTK reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 48.32% compared to the year before.
Income Statements
Revenue(TTM)1.00M
Net Income(TTM)-48.81M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.62% | ||
| ROE | -59.24% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%67.57%
Sales Q2Q%N/A
EPS 1Y (TTM)48.32%
Revenue 1Y (TTM)-82.52%
STTK Ownership
Ownership
Inst Owners56.39%
Shares75.58M
Float65.24M
Ins Owners1.46%
Short Float %2.05%
Short Ratio2.37
STTK Industry Overview
STTK operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
STTK Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.53 | 365.426B | ||
| AMGN | AMGEN INC | 13.77 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.63 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 26.24 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.4 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.43 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STTK
Company Profile
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 40 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Company Info
IPO: 2020-10-09
SHATTUCK LABS INC
500 W. 5Th Street, Suite 100
Austin TEXAS 78703 US
CEO: Taylor Schreiber
Employees: 40
Phone: 18003166660
SHATTUCK LABS INC / STTK FAQ
What does STTK do?
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 40 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Can you provide the latest stock price for SHATTUCK LABS INC?
The current stock price of STTK is 6.99 USD. The price decreased by -2.24% in the last trading session.
Does STTK stock pay dividends?
STTK does not pay a dividend.
How is the ChartMill rating for SHATTUCK LABS INC?
STTK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for STTK stock?
13 analysts have analysed STTK and the average price target is 12.65 USD. This implies a price increase of 80.94% is expected in the next year compared to the current price of 6.99.
Would investing in SHATTUCK LABS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on STTK.
What is SHATTUCK LABS INC worth?
SHATTUCK LABS INC (STTK) has a market capitalization of 528.30M USD. This makes STTK a Small Cap stock.